Asian Multicenter Prospective Study in HER2 Positive Early Breast Cancer for Detecting Minimal Residual Disease by Circulating Tumor DNA Analysis With Neoadjuvant Chemotherapy; HARMONY Study
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
This study will assess minimal residual disease (MRD) in HER2-positive early breast cancer patients in Asian countries. The purpose is to evaluate the relation between the detection rate of MRD and recurrence.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 20
Healthy Volunteers: f
View:
• Age of 20 years or older at the date of registration.
• Histological diagnosis of HER2-positive invasive breast carcinoma.
• Patients scheduled for neoadjuvant chemotherapy followed by surgery.
• Clinical Stage IIA-IIIC.
• Known hormone receptor status.
• Signed informed consent.
Locations
Other Locations
Japan
National Cancer Center Hospital, Japan
RECRUITING
Chuo-ku
Contact Information
Primary
Yuki Kojima, MD, PhD
yuukojim@ncc.go.jp
0335422511
Time Frame
Start Date: 2022-05-24
Estimated Completion Date: 2027-09-30
Participants
Target number of participants: 60
Authors
Shiino Sho
Related Therapeutic Areas
Sponsors
Leads: National Cancer Center, Japan